Moleculin Biotech Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$33.6MTTM through 30 Jun 2026
Free Cash Flow -$25.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-223.6%ROE
-151.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.41x
Net Debt-$8.9Mnet cash position
Cash & Equivalents$7.3M
Quality Metrics
Altman Z-Score-18.30
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPSFY2025: $-28.33
Dividend
No dividend
Capital Allocation
R&D Spend$19.7M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Pharmaceutical Development | $0 | 0.0% | View detailsInterim unblinded data for 45 subjects is expected in mid-2026, with full Part A unblinding of 90 subjects expected in the second half of 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.